Department of Urology, North Hospital, CHU of Saint-Etienne, Faculty of Medicine J Lisfranc, Jean Monnet University, Saint Etienne, France.
Urol Oncol. 2012 Jul-Aug;30(4):463-8. doi: 10.1016/j.urolonc.2010.04.014. Epub 2010 Sep 6.
CA9 is proven to be a powerful marker for clear cell renal cell carcinoma. The studies on CA9 have been limited to solid renal cell carcinomas (RCC). We have conducted a study of CA9 expression in renal cystic tumors. The purpose of the present study was to extend the utility of CA9 for cystic renal tumors.
Immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) were used to detect CA9 expression in cystic renal tumors. Forty-three cystic renal tumors (22 benign and 21 malignant) were included for the immunohistochemical staining. Thirty-six patients with a cystic renal mass (20 malignant and 16 benign cystic tumors) were studied to measure CA9 level in the fluid by ELISA. Sixteen cysts (9 malignant and 7 benign cysts) were subjected both to immunohistochemistry and CA9 measurement in the fluid.
Using immunohistochemical staining, all the benign cystic renal tumors including the 18 simple cyst and 4 benign multilocular cystic nephromas did not express CA9. All 13 cystic clear cell RCC were scored as strong staining for CA9. For 8 multilocular clear cell RCC, 7 were scored as strong staining for CA9 and the other one was negative. There was a significant difference in positive percentage (P < 0.001) between the 2 groups of malignant and benign cysts. For the 16 benign cysts, the mean concentration of CA9 in the fluid of cyst was 162 ± 133 pg/ml (median: 0 pg/ml; range: 0-2140 pg/ml). For the 20 malignant renal cystic tumors, the mean concentration of CA9 in the fluid of cyst was 2043 ± 62 pg/ml (median: 2,140 pg/ml; range: 1,112-2,140 pg/ml). There was a significant difference in mean concentration of CA9 between the two groups of malignant and benign cysts (P < 0.001). The presence or absence of CA9 expression measured by immunohistochemistry and ELISA test was concordant in 14 out of 16 cases (88%).
Malignant cystic renal tumors expressed strongly CA9 while the benign renal cysts did not express CA9. CA9 can be detected in the fluid of malignant cystic renal tumors. CA9 is a promising molecular marker to differentiate the malignant cystic renal tumors from the benign cysts.
CA9 已被证实是肾透明细胞癌的有力标志物。CA9 的研究仅限于实体肾细胞癌(RCC)。我们对囊性肾肿瘤中的 CA9 表达进行了研究。本研究的目的是扩展 CA9 在囊性肾肿瘤中的应用。
采用免疫组织化学和酶联免疫吸附试验(ELISA)检测囊性肾肿瘤中 CA9 的表达。共纳入 43 例囊性肾肿瘤(22 例良性和 21 例恶性)进行免疫组织化学染色。36 例囊性肾肿块患者(20 例恶性和 16 例良性囊性肿瘤)通过 ELISA 检测囊液中 CA9 水平。16 个囊肿(9 个恶性和 7 个良性囊肿)均进行免疫组织化学和 CA9 测量。
免疫组织化学染色显示,所有良性囊性肾肿瘤(包括 18 个单纯性囊肿和 4 个良性多房囊性肾细胞瘤)均不表达 CA9。13 例囊性透明细胞 RCC 均为 CA9 强染色。8 例多房透明细胞 RCC 中,7 例 CA9 强染色,1 例阴性。两组恶性和良性囊肿的阳性百分比有显著差异(P<0.001)。在 16 例良性囊肿中,囊液中 CA9 的平均浓度为 162±133pg/ml(中位数:0pg/ml;范围:0-2140pg/ml)。在 20 例恶性肾囊性肿瘤中,囊液中 CA9 的平均浓度为 2043±62pg/ml(中位数:2140pg/ml;范围:1112-2140pg/ml)。两组恶性和良性囊肿之间的 CA9 平均浓度有显著差异(P<0.001)。免疫组织化学和 ELISA 检测的 CA9 表达的存在或缺失在 16 例中有 14 例(88%)一致。
恶性囊性肾肿瘤强烈表达 CA9,而良性肾囊肿不表达 CA9。CA9 可在恶性囊性肾肿瘤的囊液中检测到。CA9 是鉴别恶性囊性肾肿瘤和良性囊肿的有前途的分子标志物。